2021-02-16
Photo by United Nations on Unsplash.com
The stories of seemingly promising medications that did not pan out as treatments for COVID-19, including, most famously, the malaria medication hydroxychloroquine, has left many researchers wary. However, here is some good news in the fight against COVID-19.
According to certain topline results from a clinical trial in Canada, colchicine, an inexpensive oral tablet already known and used to treat gout, improved COVID-19 outcomes for patients with mild cases and reduced the risk of complications and death by 21%.
What Is Colchicine?
Colchicine is an oral anti-inflammatory that has long been prescribed for gout, a form of arthritis.
The most commonly prescribed treatment for a gout attack is an anti-inflammatory painkiller, although not everyone is able to take this kind of medicine.
Colchicine (Colcrys, Mitigare, Colgout) is an alternative treatment for gout attacks for those people who cannot take the anti-inflammatory painkillers.
It works by reducing the number of white blood cells which travel into the inflamed areas. This helps break the cycle of inflammation and reduces the swelling and pain of the gout attack.
Is This the First Hope for Patients Who Have Early COVID-19?
It’s all part of a growing belief that the worst effects of the coronavirus infection are caused not by the virus itself, but by a massive overreaction of the immune system, known as a cytokine storm.
In a cytokine storm, the immune system goes into overdrive — flooding the body with proteins (cytokines) that trigger widespread inflammation. That causes often fatal damage to organs.
Colchicine is just one of several anti-inflammatory medications currently in clinical trials for treating COVID-19.
The Canadian study showed the effectiveness of treatment using colchicine to prevent the phenomenon of the major inflammatory storm and reduce complications related to COVID-19.
What Have the Researchers Found?
The study was deployed across Canada, the U.S., Europe, South America, and South Africa. It randomized participants (double-blind) to colchicine 0.5 mg or a matching placebo twice daily for the first 3 days and then once daily for the last 27 days.
To keep those patients isolated at home, the study has an unusual “contactless” design: Patients will receive the medication by courier and have follow-up visits via video or phone.
Dr. Jean-Claude Tardif, who led the above study from Montreal Heart Institute, said “This is a major scientific discovery. Colchicine is the first effective oral medication to treat out-of-hospital patients.”
There was a significant effect among the 4,159 of 4,488 patients who had their diagnosis of COVID-19 confirmed by a positive PCR test:
What are the side effects of colchicine?
Some physicians also warned about the potential for misuse of the findings and attendant risks.
While colchicine usually causes only mild side effects including diarrhea and nausea, it can in rare instances be toxic and even fatal if a person is prescribed too high of a dose.
It can also be contraindicated for someone with certain kidney problems and can interact with common medications like certain antibiotics or blood pressure medications.
If you are diagnosed early with COVID-19 and interested in this medication, talk to your doctor, pharmacist, or health care provider for more information.
About Cheapomeds
Cheapomeds is certified by Canadian International Pharmacy Association. No hidden costs, no membership fees, just great savings on all your prescription needs.
Next time before you place order, especially on brand name medications, call them to see if they can match the price and help you save up to 80% on your medications.
References:
*Use the same email you used for your CheapoMeds.com account. (If you have made a purchase, you already have an account.) If you don't have an account, create one now, and then return to this page.
Cheapomeds
Suite# 357
23 - 845 Dakota Street
Winnipeg, Manitoba
Canada R2M 5M3
Email:Report Abuse:Phone:Toll Free: 1-844-4CHEAPO (424-3276)
International: 1-403-388-8780